Residual Disease
Oncology·MeSH: Neoplasm, Residual
8 drugs in development·6 companies·6 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| clonoSEQ | Adaptive Biotechnologies Corp (ADPT) |
Phase 3(1)
| Drug | Company |
|---|---|
| Adjuvant chemotherapy | Valneva SE (VALN) |
Phase 2(1)
| Drug | Company |
|---|---|
| eli-002 | Elicio Therapeutics, Inc. (ELTX) |
Preclinical(2)
Unknown(1)
N/A(1)
| Drug | Company |
|---|---|
| Neoadjuvant Chemotherapy | Valneva SE (VALN) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| eli-002 2p | Elicio Therapeutics, Inc. (ELTX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Residual Disease?
BioSniper tracks 8 drugs in development for Residual Disease across 6 companies.
How many clinical trials target Residual Disease?
There are 6 clinical trials targeting Residual Disease tracked by BioSniper.
Deep-dive into Residual Disease
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis